SUBSCRIBE
SUBSCRIBE
News   Drug Development

Spectrum Pharmaceuticals, Inc. to End Development of Enlarged-Prostate Drug; To Save More Than $40 Million from Termination

January 27, 2010 | 
1 min read

Bookmark and Share

Reuters -- Spectrum Pharmaceuticals Inc said it will stop developing its experimental treatment for enlarged prostate to cut costs and focus on other drug candidates.

Clinical research Phase II
MORE ON THIS TOPIC
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to Pfizer's office in Belgium
Breast cancer
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Dollar banknote cut into pieces on a yellow background
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac
2D illustration showing scientists' hands editing a DNA strand
Gene editing
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
March 11, 2025
 · 
2 min read
 · 
Tristan Manalac